FOLFOXIRI plus bevacizumab (bev) as upfront treatment for metastatic colorectal cancer (mCRC) patients (pts) with initially unresectable liver-limited disease (LLD)

被引：0
|
作者：
Casagrande, M. [1 ,2 ]
Cremolini, C. [3 ]
Zucchelli, G. [3 ]
Bergamo, F. [4 ]
Ferrari, L. [1 ,2 ]
Pietrantonio, F. [5 ]
Lonardi, S. [4 ]
Loupakis, F. [3 ]
Masi, G. [3 ]
Pella, N. [1 ,2 ]
Intini, R. [4 ]
Salvatore, L. [3 ]
Tomasello, G. [6 ]
Pagani, F. [3 ]
Pellino, A. [3 ]
Dell'Aquila, E. [7 ]
Ginocchi, L. [8 ]
Milione, M. [9 ]
Fea, E. [10 ]
Pellegrinelli, A. [9 ]
Falcone, A. [3 ]
机构：
[1] Univ Udine, Dept Oncol, Udine, Italy
[2] Gen Hosp, Udine, Italy
[3] Azienda Osped Univ Pisana, Ist Toscano Tumori, UO Oncol Med 2, Pisa, Italy
[4] Ist Oncol Veneto IRCCS, UOC Oncol Med 1, Dipartimento Oncol Clin & Sperimentale, Padua, Italy
[5] Fdn IRCSS, Dipartimento Oncol Med, Ist Nazl Tumori, Milan, Italy
[6] ASST Osped Cremona, UO Oncol, Cremona, Italy
[7] Univ Campus Biomed, Rome, Italy
[8] UO Oncol Med Azienda Toscana Nord Ovest, Dipartimento Oncol, Pontedera, Italy
[9] Fdn IRCCS Ist Nazl Tumori Milano, Dipartimento Patol Diagnost & Lab, Milan, Italy
[10] AOS Croce & Carle Cuneo, Oncol Med, Cuneo, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw335.5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
D05
引用
收藏
页数：1
相关论文
共 50 条
  • [1] FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
    Antoniotti, Carlotta
    Vetere, Guglielmo
    Cremolini, Chiara
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (18)
  • [2] Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver-limited metastatic colorectal cancer (mCRC)
    Ongaro, E.
    Rossini, D.
    Pietrantonio, F.
    Morano, F.
    de Braud, F.
    Mazzaferro, V.
    Corti, F.
    Randon, G.
    Raimondi, A.
    Battaglia, L.
    Morelli, L.
    Urbani, L.
    Masi, G.
    Moretto, R.
    Antoniotti, C.
    Marmorino, F.
    Borelli, B.
    Zucchelli, G.
    Boccaccino, A.
    Cremolini, C.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [3] FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO
    Cremolini, C.
    Rossini, D.
    Antoniotti, C.
    Pietrantonio, F.
    Lonardi, S.
    Salvatore, L.
    Marmorino, F.
    Borelli, B.
    Ambrosini, M.
    Barsotti, G.
    Di Stefano, B.
    Masi, G.
    Boccaccino, A.
    Tamberi, S.
    Tamburini, E.
    Frassineti, L. G.
    Simionato, F.
    Fontanini, G.
    Boni, L.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1294 - S1295
  • [4] FOLFOXIRI plus bevacizumab (BEV) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Preliminary safety results from the OPAL study
    Stein, Alexander
    Atanackovic, Djordje
    Hildebrandt, Bert
    Stuebs, Patrick
    Steffens, Claus-Christoph
    Brugger, Wolfram
    Hapke, Gunnar
    Illerhaus, Gerald
    Bluemner, Ernst
    Bokemeyer, Carsten
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [5] FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.
    Falcone, Alfredo
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Salvatore, Lisa
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Loupakis, Fotios
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] FOLFOXIRI plus bevacizumab (BEV) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Final survival and pharmacogenomic profiling results from the OPAL study
    Bokemeyer, C.
    Atanackovic, D.
    Stoehlmacher, J.
    Hildebrandt, B.
    Stuebs, P.
    Steffens, C.
    Brugger, W.
    Hapke, G.
    Illerhaus, G.
    Bluemner, E.
    Stein, A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 100 - 100
  • [7] FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer A Systematic Review and Pooled Analysis
    Tomasello, Gianluca
    Petrelli, Fausto
    Ghidini, Michele
    Russo, Alessandro
    Passalacqua, Rodolfo
    Barni, Sandro
    [J]. JAMA ONCOLOGY, 2017, 3 (07)
  • [8] Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable
    Ongaro, Elena
    Cremolini, Chiara
    Rossini, Daniele
    Corti, Francesca
    Pagani, Filippo
    Morelli, Luca
    Urbani, Lucio
    Masi, Gianluca
    Sposito, Carlo
    Filippi, Beatrice
    Borelli, Beatrice
    Zucchelli, Gemma
    Moretto, Roberto
    Boccaccino, Alessandra
    Solaini, Leonardo
    de Braud, Filippo
    Mazzaferro, Vincenzo
    Falcone, Alfredo
    Cucchetti, Alessandro
    Pietrantonio, Filippo
    [J]. ESMO OPEN, 2019, 4 (02)
  • [9] FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.
    Antoniotti, Carlotta
    Rossini, Daniele
    Pietrantonio, Filippo
    Salvatore, Lisa
    Marmorino, Federica
    Ambrosini, Margherita
    Lonardi, Sara
    Bensi, Maria
    Moretto, Roberto
    Tamberi, Stefano
    Toma, Ilaria
    Passardi, Alessandro
    De Grandis, Maria Caterina
    Conca, Veronica
    Palermo, Federica
    Cappetta, Alessandro
    Catteau, Aurelie
    Boni, Luca
    Galon, Jerome
    Cremolini, Chiara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Impact of FOLFOXIRI plus bevacizumab on resectability and survival in patients with initially unresectable liver metastases from colorectal cancer.
    Shimada, M.
    Nishioka, M.
    Hanaoka, J.
    Mori, H.
    Ikemoto, T.
    Imura, S.
    Morine, Y.
    Utsunomiya, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345